Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$22.82 USD
-0.22 (-0.95%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $22.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
RCKT 22.82 -0.22(-0.95%)
Will RCKT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RCKT
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Other News for RCKT
Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
Maintaining Buy on Rocket Pharmaceuticals: Temporary Setback with Strong Long-Term Prospects
Buy Rating Affirmed for Rocket Pharmaceuticals Amid Manageable FDA Hurdle
Optimistic Outlook for Rocket Pharmaceuticals’ KRESLADI Despite FDA Request for Additional CMC Information
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session